Retrospective Cohort Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 343-351
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.343
Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
Erkan Kayikcioglu, Ramazan Oğuz Yüceer, Bulent Cetin, Kamuran Yüceer, Nermin Karahan
Erkan Kayikcioglu, Department of Medical Oncology, Suleyman Demirel University, Isparta 32260, Turkey
Ramazan Oğuz Yüceer, Department of Pathology, Isparta City Hospital, Isparta 32360, Turkey
Bulent Cetin, Kamuran Yüceer, Department of Internal Medicine, Suleyman Demirel University, Faculty of Medicine, Isparta 32360, Turkey
Nermin Karahan, Department of Pathology, Suleyman Demirel University, Isparta 32360, Turkey
Author contributions: Kayikcioglu E contributed to conceptualization; Yüceer RO, Kayikcioglu E, Karahan N, and Cetin B contributed to formal analysis and investigation; Kayikcioglu E and Cetin B contributed to supervision; Kayikcioglu E, Yüceer RO, and Yüceer K contributed to resources; Yüceer K contributed to visualization; Kayikcioglu E, Yüceer RO, Yüceer K, Karahan N, and Cetin B contributed to writing and original draft preparation; Kayikcioglu E, Karahan N, and Cetin B contributed to reviewing and editing.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Suleyman Demirel University (Approval No. 01/04/2022-102).
Informed consent statement: The informed consent was obtained from the patients.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Erkan Kayikcioglu, MD, Assistant Professor, Department of Medical Oncology, Suleyman Demirel University, Cunur, Suleyman Demirel Caddesi, Isparta 32260, Turkey. drkayikcioglu@yahoo.com
Received: October 29, 2022
Peer-review started: October 29, 2022
First decision: December 30, 2022
Revised: January 2, 2023
Accepted: January 23, 2023
Article in press: January 23, 2023
Published online: February 15, 2023
Processing time: 108 Days and 13.8 Hours
Core Tip

Core Tip: Zolbetuximab is a new antibody drug targeting the cell surface protein claudin 18.2 (CLDN18.2) expressed by gastric cancer cells. CLDN18.2 expression, identifying the patient population who are susceptible to zolbetuximab, is discordant in different studies. The present study aimed to research the expression ratio of CLDN18.2 and its prognostic value for overall survival in patients with gastric adenocarcinoma in a single center located in Turkey.